Memory and Attention Adaptation Training-Geriatrics (MAAT-G)

NCT04230941 | Completed Results

• 2 other identifiers: UCCS191021K76AG064394-01
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising treatment for CRCD that improves perceived cognition in younger cancer survivors, but needs to be adapted for older adults to address their unique needs. The proposed study will adapt MAAT for older adults using feedback from key stakeholders (older adults with cancer and their caregivers), and test usability of the intervention.

Conditions

Cancer-related Problem/Condition; Cognitive Impairment

Outcome Measures

Primary Outcomes (2)

• System Usability Scale (SUS)

  The System Usability Scale is a metric to evaluate the usability of the intervention (Patients) and is scored 0 (minimum) to 100 (maximum). Higher scores indicate greater usability. A mean score \>68 is consisted with optimal usability.

  Post-Intervention (up to 2 weeks)

• Experience Interview

  Semi-structured interview with patients and caregivers about experience with MAAT-G. (Patients and caregivers) Qualitative Analysis of transcripts from participant/caregiver interviews will be analyzed for themes on intervention benefit and barriers and facilitators.

  Post-Intervention (up to 2 weeks)

Study Arms (1)

MAAT-G Intervention

EXPERIMENTAL

MAAT-G Workshops \& participant workbook use (8 workshops)

Behavioral: MAAT-G

Interventions

MAAT-G BEHAVIORAL

Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.

MAAT-G Intervention

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Have a diagnosis of invasive breast cancer
• Planned to receive systemic therapy for breast cancer or actively receiving systemic therapy for breast cancer with two additional cycles remaining.
• Be age 65 or older
• Able to provide informed consent
• Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)

You may not qualify if:

• Have surgery planned within 3 months of consent
• Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
• Patients with breast cancer receiving endocrine therapy as their only systemic therapy will not be eligible.
• \. Selected by the patient when asked if there is a "family member, partner, friend or caregiver \[age 21 or older\] with whom you discuss or who can be helpful in health-related matters;" patients who cannot identify such a person ("caregiver") will remain eligible for the study.
• \. Caregivers unable to understand the consent form due to cognitive, health or sensory impairment will be excluded

Sponsors & Collaborators

• University of Rochester: lead
• National Institute on Aging (NIA): collaborator

Study Sites (1)

University of Rochester Medical Center

Rochester, New York, 14642, United States

Location

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Results Point of Contact

• Title: Allison Magnuson, (Principal Investigator), Associate Professor of Medicine
• Organization: University of Rochester

allison_magnuson@urmc.rochester.edu

585-276-7155

Study Officials

• Allison Magnuson

  University of Rochester

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor of Medicine

Model Details: Usability

Study Record Dates

• First Submitted: January 13, 2020
• First Posted: January 18, 2020
• Study Start: June 12, 2020
• Primary Completion: April 1, 2021
• Study Completion: February 1, 2022
• Last Updated: November 13, 2023
• Results First Posted: July 19, 2023

Record last verified: 2023-11

Locations

US (1)